A Study of VERVE-102 in Patients With Familial Hypercholesterolemia or Premature Coronary Artery Disease

What this study is about

VT-10201 is an Open-label, Phase 1b, Single-ascending Dose Study That Will Evaluate the Safety of VERVE-102 Administered to Patients With Heterozygous Familial Hypercholesterolemia (HeFH) or Premature Coronary Artery Disease (CAD) Who Require Additional Lowering of LDL-C. VERVE-102 Uses Base-editing Technology Designed to Disrupt the Expression of the PCSK9 Gene in the Liver and Lower Circulating PCSK9 and LDL-C. This Study is Designed to Determine the Safety and Pharmacodynamic Profile of VERVE-102 in This Patient Population.

Who can join (things the study team will check)

✅ You may be able to join if…

• Diagnosis of HeFH or premature CAD

🚫 You may not be able to join if…

• Homozygous familial hypercholesterolemia
• Active or history of chronic liver disease
• Current treatment with PCSK9 inhibitor or prior treatment within specified timeframe
• Clinically significant or abnormal laboratory values as defined by the protocol

Where this trial is running

• Clinical Study Center, Dothan, Alabama, United States
• Clinical Study Center, Pomona, California, United States
• Clinical Study Center, Boca Raton, Florida, United States
• Clinical Study Center, Jacksonville, Florida, United States
• Clinical Study Center, Winter Park, Florida, United States
• Clinical Study Center, High Point, North Carolina, United States
• Clinical Study Center, DeSoto, Texas, United States
• Clinical Study Center, Renton, Washington, United States
• Clinical Study Center, Adelaide, Australia
• Clinical Study Center, Melbourne, Australia
• Clinical Study Center, Sydney, Australia
• Clinical Study Center, Chicoutimi, Canada

+ 12 more sites.

Who to contact

Clinical Development · 781-970-6833 · verve102clinicaltrials@lists.lilly.com

It's completely normal to call and ask questions before deciding anything. Mention the study ID: NCT06164730.